Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
North America Biocatalysts Market Report Overview
The North America biocatalysts market attained a value of 51.06 KMT in 2025 and is projected to expand at a CAGR of 5.60% through 2035. The market is further expected to achieve 88.05 KMT by 2035, supported by rising adoption of enzyme-based manufacturing across food and beverage processing, biopharmaceutical synthesis, biofuel production, and industrial cleaning formulations, as producers across the United States and Canada scale fermentation capacity, pursue platform consolidation, and expand biocatalytic drug-manufacturing capabilities to meet demand for sustainable, lower-emission chemical processes.
Key Market Trends and Insights
- The Oxidoreductases type segment is forecast to grow at a CAGR of 9.40% through 2035, as pharmaceutical and biofuel manufacturers scale engineered ketoreductase and dehydrogenase enzymes for chiral synthesis and renewable-fuel conversion processes.
- The Biopharmaceuticals application segment is forecast to expand at a CAGR of 10.10%, driven by accelerating adoption of biocatalytic routes for active pharmaceutical ingredient synthesis in place of conventional chemical catalysis.
- Canada is emerging as the fastest-growing country market at an estimated CAGR of 8.70%, supported by expanding federal biomanufacturing investment and growing life-sciences production capacity across the country.
Market Size & Forecast
- Market Size in 2025: 51.06 KMT
- Projected Market Size in 2035: 88.05 KMT
- CAGR from 2026 to 2035: 5.60%
- Fastest-Growing Regional Market: Canada
Sustained biomanufacturing investment continues to strengthen production capacity across the North America biocatalysts market, as governments and specialty manufacturers commit new capital to enzyme-adjacent life-sciences infrastructure. Evonik disclosed in September 2026 a CAD 150 million (approximately USD 108 million) investment in a new good manufacturing practice drug-product facility in Canada, part of the broader wave of biomanufacturing capacity additions across the country that is expected to benefit adjacent enzyme and biocatalyst production capabilities. This investment climate is reinforcing Canada's position as an increasingly important production base within the region alongside the United States' established enzyme-manufacturing and biotechnology footprint. This momentum is consistent with Canada's standing as the region's fastest-expanding country market, projected to grow at an 8.70% CAGR over the forecast period.
Capacity expansion among leading enzyme producers is reinforcing global supply capabilities that ultimately benefit adjacent biocatalyst production. Novonesis disclosed on September 2, 2026, a EUR 600 million investment in a next-generation enzyme production facility in Patalganga, India, expected online by 2030 to supply biofuel, household-care, and food-and-beverage enzyme demand across its global customer base. The investment illustrates the scale of capital major biosolutions companies are committing to enzyme-production capacity as global demand accelerates, a pattern that parallels the fermentation and formulation capacity build-out already underway among North American producers. This expansion trajectory reflects a broader industry pattern of enzyme manufacturers scaling production platforms to meet rising cross-industry biocatalyst demand.
Portfolio restructuring is also underway among diversified life-sciences producers active in the segment. DSM-Firmenich disclosed on February 9, 2026, an agreement to divest its Animal Nutrition and Health business to CVC Capital Partners for approximately EUR 2.2 billion, retaining a 20% equity stake as part of its continued transformation into a more focused nutrition, health, and beauty company. The company indicated the transaction reflects a broader strategic shift toward higher-margin specialty ingredient and flavor businesses, while CVC brings dedicated capital and operational focus to the divested animal-nutrition platform going forward. This restructuring reflects a broader industry pattern of diversified life-sciences producers streamlining non-core portfolios to sharpen strategic focus and capital allocation.
Compound Annual Growth Rate
5.6%
Value in KMT
2026-2035
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Trends and Recent Developments
Codexis entered into an agreement with a pioneering siRNA drug innovator to leverage its ECO Synthesis manufacturing platform to create stereo-defined siRNA fragments, applying its engineered biocatalyst technology to a fast-growing class of RNA-based therapeutics. The agreement extends Codexis's enzyme-engineering capabilities beyond small-molecule active pharmaceutical ingredients into oligonucleotide manufacturing, an area of growing pharmaceutical industry interest, and builds on the company's established base of engineered ketoreductase and transaminase biocatalyst platforms. Companies can leverage engineered biocatalyst platforms to expand into adjacent, high-value therapeutic modalities and diversify revenue beyond traditional small-molecule synthesis. Headquartered in Redwood City, California, Codexis has built this expansion on its proprietary CodeEvolver protein-engineering platform since the company's founding in 2002.
Novonesis celebrated the major expansion of its West Allis, Wisconsin production facility, strengthening its North American dairy innovation and manufacturing capabilities in September 2026. The expanded site supports growing demand for dairy-processing enzymes such as rennet and lactase across the United States and Canada, reinforcing the company's domestic production footprint amid rising demand for enzyme-based dairy formulation among regional food and beverage manufacturers. Companies can leverage regionally located production expansions to shorten supply chains and respond faster to evolving North American dairy-processing customer requirements. Novonesis, formed in 2024 through the Novozymes-Chr. Hansen merger and headquartered in Bagsværd, Denmark, continues directing capital toward its North American manufacturing network.
BRAIN Biotech AG reported in its half-year fiscal 2025/26 results, released in May 2026, that its BRAINBiocatalysts enzyme products segment delivered strong revenue expansion while the company maintained its full-year guidance. The results followed the September 2025 appointment of Johan Jansén-Storbacka as Executive Vice President overseeing the segment's enzyme products operations, a leadership addition aimed at accelerating commercial growth across the group's specialty and industrial enzyme portfolio. Companies can leverage dedicated segment leadership to sharpen commercial focus and sustain growth momentum across specialty enzyme product lines. This performance reflects a broader pattern of specialty enzyme producers strengthening leadership and product pipelines to capture growing pharmaceutical and industrial biocatalysis demand.
Sterling Pharma Solutions joined a GBP 4 million Innovate UK funded initiative in February 2026, called Biocat Copilot, aimed at building an integrated digital artificial-intelligence ecosystem for sustainable medicines manufacturing through biocatalysis. The programme, led by biocatalysis specialist Disyn Biotec, also includes GSK and Bristol Myers Squibb among its collaborating partners, with Sterling contributing process development, scale-up, and manufacturing expertise to the initiative. Companies can leverage collaborative, publicly funded innovation programmes to accelerate adoption of AI-assisted biocatalysis platforms without bearing the full development cost alone. Participation in such multi-partner consortia reflects growing recognition that digital and AI-assisted tools can accelerate biocatalysis development while spreading technical and financial risk.
DSM-Firmenich AG Completes Divestment of Feed Enzymes Alliance Stake
DSM-Firmenich completed the sale of its stake in the Feed Enzymes Alliance to Novonesis for USD 1.5 billion in June 2025, exiting a shared enzyme-production structure to sharpen its focus on its core nutrition, health, and flavor and fragrance portfolio. The transaction followed a February 2025 agreement between the two companies and reflects a broader industry pattern of portfolio consolidation as diversified ingredient producers streamline enzyme-adjacent business lines. Companies can leverage divestment of non-core alliance stakes to concentrate capital and management attention on higher-margin core ingredient platforms. DSM-Firmenich, formed in 2023 through the Royal DSM-Firmenich merger and dual-headquartered in the Netherlands and Switzerland, continues prioritizing its remaining nutrition and flavor businesses.
BASF SE Reviews Strategic Options for Feed Enzymes Business
BASF confirmed in October 2025 that it is seeking a new ownership structure for its feed enzymes business, which includes established phytase, xylanase, glucanase, and mannanase product lines within its Nutrition & Health segment. The company noted the unit has significantly outpaced broader market growth in recent years and stated it seeks a partner for whom feed enzymes represent a strategic focus area for driving further innovation. Companies can leverage a defined strategic-review process to attract partners who can unlock further growth in a high-performing but non-core enzyme business line. Founded in 1865 and headquartered in Ludwigshafen am Rhein, Germany, BASF manufactures these enzyme lines through its BASF Enzymes unit within its chemical portfolio.
Almac Group Limited Expands US Analytical Capacity in Pennsylvania
Almac Group expanded its US analytical capacity in August 2025 by installing new stability chambers at its Souderton, Pennsylvania site, adding infrastructure that supports biocatalytic process development and quality testing for pharmaceutical clients across North America. The investment builds on the company's established Pennsylvania manufacturing and development footprint, reinforcing its ability to support biocatalysis-based drug-substance programs for clients scaling from clinical to commercial production volumes. Companies can leverage incremental analytical-capacity investment to support growing biocatalysis-based drug development pipelines without committing to a full facility rebuild. Such incremental investments in quality and analytical infrastructure are increasingly common among contract-development organizations supporting biocatalysis programs without the capital burden of new construction.
Amano Enzyme Inc. Showcases Enzyme Innovations at SupplySide Global 2025
Amano Enzyme USA showcased its Protein Glutaminase "Amano" 500 and CheeseMax PB microbial enzymes at SupplySide Global 2025, held in Las Vegas in October 2025, highlighting formulation solutions for plant-based dairy alternatives aimed at North American food and beverage manufacturers. The company also highlighted its Elgin, Illinois facility expansion, completed in 2025, which added approximately 29,827 square feet of production and technical-services space supporting North, Central, and South American markets. Companies can leverage trade-show product showcases alongside recent capacity expansions to demonstrate both innovation and manufacturing readiness to prospective customers. These combined product and infrastructure announcements underscore how microbial-enzyme suppliers pair innovation showcases with tangible capacity investment to reinforce customer confidence regionally.
North America Biocatalysts Industry Segmentation
This Expert Market Research's Report titled "North America Biocatalysts Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Hydrolases
- Oxidoreductases
- Transferases
- Others
Key Insight: Hydrolases accounts for the largest share of the North America biocatalysts market, reflecting sustained demand for protease, amylase, and lipase-class enzymes across food processing and industrial cleaning applications, reinforced by BASF's July 2025 expansion of its Lavergy liquid enzyme portfolio with new lipase, cellulase, and amylase products for the laundry and cleaning industry. Oxidoreductases is the fastest-growing type segment at an estimated CAGR of 9.40%, as pharmaceutical manufacturers scale engineered biocatalysts, illustrated by Codexis, Inc.'s January 2026 evaluation agreement with Axolabs to assess its ECO Synthesis platform for oligonucleotide-therapeutic manufacturing. Transferases supports specialty applications including nucleotide and amino-acid synthesis across pharmaceutical and fine-chemical manufacturing. Others captures niche enzyme classes, including lyases and isomerases, serving specialized industrial biocatalysis applications. Across all four type segments, competitive positioning increasingly depends on the breadth of enzyme-engineering platforms available to service food-industrial and pharmaceutical-grade biocatalysis demand.
Market Breakup by Source
- Microorganisms
- Plants
- Animals
Key Insight: Microorganisms accounts for a substantial share of the market, reflecting the scalability and cost efficiency of fermentation-based enzyme production, illustrated by Amano Enzyme USA's March 2025 addition of a dedicated technical sales representative supporting microbial enzyme applications in plant-based dairy, flavors, and protein modification across North American and Latin American accounts. Plants is the fastest-growing source segment at an estimated CAGR of 8.20%, as clean-label and non-GMO formulation demand encourages manufacturers to develop plant-derived enzyme alternatives alongside traditional microbial platforms. Animals continues to represent a smaller, specialized share of the market, supplying enzymes such as pancreatin and rennet derivatives for select food-processing and pharmaceutical applications. Across all three source categories, sourcing strategy increasingly balances production cost, sustainability positioning, and regulatory requirements across food, personal-care, and pharmaceutical applications.
Market Breakup by Application
- Food and Beverages
- Cleaning Agent
- Biofuel Production
- Agriculture and Feed
- Biopharmaceuticals
- Others
Key Insight: Food and Beverages accounts for the largest share of the market, supported by widespread enzyme use in baking, dairy, and beverage processing, reinforced by AB Enzymes GmbH's December 2025 achievement of the EcoVadis Platinum medal, placing it among the top 1% of assessed companies for sustainability performance across its food-enzyme supply chain. Biopharmaceuticals is the fastest-growing application segment at an estimated CAGR of 10.10%, as biocatalytic drug-manufacturing adoption accelerates, illustrated by SK pharmteco's March 2026 strategic collaboration with enzyme-discovery specialist Prozomix, integrating Prozomix's biocatalysis enzyme toolkit into SK pharmteco's small-molecule development and manufacturing services across its US, European, and South Korean facilities. Cleaning Agent applications continue to draw on protease and lipase enzymes for detergent formulation, while Biofuel Production relies on cellulase and amylase enzymes for lignocellulosic and starch-based ethanol conversion. Agriculture and Feed applications use phytase and xylanase enzymes to improve feed digestibility and nutrient absorption. Others captures smaller applications including textile processing, leather treatment, and pulp and paper manufacturing. Across these application categories, adoption decisions increasingly hinge on enzyme performance consistency, regulatory alignment, and total cost of ownership relative to chemical processing alternatives.
Market Breakup by Country
- United States
- Canada
Key Insight: United States accounts for the largest share of the North America biocatalysts market at approximately 79% in 2025, supported by an established base of enzyme manufacturing, biotechnology research, and pharmaceutical biocatalysis infrastructure, reinforced by AB Enzymes GmbH's April 2026 IFU Innovation Award win for its enzymatic citrus by-product conversion technology, presented at the IFU Juice Conference in Orlando, Florida. Canada is the fastest-growing country market at an estimated CAGR of 8.70%, supported by expanding federal biomanufacturing investment, illustrated by Evonik's September 2026 disclosure of a CAD 150 million good manufacturing practice drug-product facility investment in the country. Together, these dynamics illustrate a regional market where an established United States manufacturing base and an accelerating Canadian investment climate jointly expand production capacity.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Purchase the Regional Overview for USD 1099
If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America Biocatalysts Market Share
By type, hydrolases leads the market while oxidoreductases grows fastest as pharmaceutical manufacturers scale engineered biocatalyst platforms
Hydrolases continues to account for the largest share of the North America biocatalysts market, reflecting deep-rooted demand for protease, amylase, and lipase enzymes across food processing, detergent formulation, and textile applications. Novonesis's completed acquisition of dsm-firmenich's share of the Feed Enzyme Alliance, finalized in June 2025 for USD 1.5 billion, brought phytase, xylanase, glucanase, and mannanase hydrolase-class enzymes fully under a single commercial platform, strengthening supply continuity for North American agriculture and feed customers that had previously relied on a jointly operated alliance structure spanning both companies' production networks. This scale advantage continues to attract sustained capital investment from established producers seeking to defend leadership positions across food-processing, detergent, and textile-enzyme end markets.
Oxidoreductases is growing at a fast pace across the market at a projected CAGR of 9.40%, as pharmaceutical manufacturers increasingly substitute chemical oxidation and reduction steps with engineered ketoreductase and dehydrogenase biocatalysts. Codexis, Inc. extended its enzyme-engineering leadership in September 2026 by signing an agreement with a siRNA drug innovator to apply its ECO Synthesis manufacturing platform to stereo-defined oligonucleotide fragment production, demonstrating how oxidoreductase and related engineered-enzyme technology is expanding beyond traditional small-molecule chiral synthesis into new therapeutic modalities. This trajectory parallels the 10.10% CAGR forecast for the Biopharmaceuticals application segment, both reflecting accelerating pharmaceutical-industry adoption of engineered biocatalytic manufacturing routes.
By source, microorganisms leads the market while plants grows fastest given rising clean-label and non-GMO enzyme demand
Microorganisms continues to account for a substantial share of the market, as fermentation-based production offers manufacturers scalable, cost-efficient enzyme output relative to plant- or animal-derived alternatives. Amano Enzyme Inc. reinforced its microbial-enzyme production base in October 2025 by highlighting its Elgin, Illinois facility expansion, completed in 2025, which added approximately 29,827 square feet of production and technical-services capacity supporting North, Central, and South American customers, alongside new microbial enzyme launches showcased at SupplySide Global 2025 in Las Vegas. This production efficiency continues to make microbial fermentation the preferred sourcing route for manufacturers balancing cost, scalability, and consistent enzyme-activity requirements across application categories.
Plants is growing at a fast pace across the market at a projected CAGR of 8.20%, as formulators respond to consumer and regulatory preference for clean-label, non-GMO enzyme sourcing across food, beverage, and personal-care applications. Industry-wide research and development investment into plant-derived enzyme extraction and stabilization techniques is accelerating as manufacturers seek to diversify their sourcing base beyond traditional microbial fermentation platforms, supporting broader adoption of plant-based biocatalysts across sensitive end-use categories such as infant nutrition and natural personal-care formulations. This shift is expected to continue reshaping ingredient-sourcing strategies as sustainability credentials and traceability increasingly factor into procurement decisions for sensitive consumer-facing formulations.
By application, food and beverages leads the market while biopharmaceuticals grows fastest given accelerating biocatalytic drug-manufacturing adoption
Food and Beverages continues to account for the largest share of the market, reflecting the breadth of enzyme use across baking, brewing, dairy, and beverage-clarification processes. AB Enzymes GmbH reinforced its position in the segment in December 2025 by earning the EcoVadis Platinum medal, placing it among the top 1% of assessed companies for environmental, labor, ethics, and sustainable-procurement performance, a credential that increasingly influences food and beverage manufacturers' enzyme-supplier selection decisions across North America. Sustainability credentials of this kind are becoming an increasingly important differentiator as food and beverage manufacturers formalize supplier environmental and governance requirements across procurement.
Biopharmaceuticals is growing at a fast pace across the market at a projected CAGR of 10.10%, as drugmakers adopt biocatalytic synthesis routes to reduce solvent use and improve manufacturing efficiency relative to conventional chemical catalysis. Sterling Pharma Solutions Limited joined the GBP 4 million Innovate UK Biocat Copilot programme in February 2026 alongside GSK and Bristol Myers Squibb to develop an AI-assisted digital biocatalysis platform, underscoring how collaborative innovation is accelerating biocatalytic adoption across pharmaceutical manufacturing. This growth trajectory mirrors the 9.40% CAGR projected for the Oxidoreductases type segment, highlighting the pharmaceutical industry's expanding reliance on engineered biocatalytic manufacturing routes.
North America Biocatalysts Market Regional Analysis
United States commands the largest country-level share of the North America biocatalysts market at approximately 79% in 2025.
This is supported by Almac Group Limited's August 2025 installation of new stability chambers at its Souderton, Pennsylvania site, expanding US analytical capacity dedicated to biocatalysis-based drug-substance development and quality testing. This investment reinforces the scale behind the country's roughly 79% share of regional market value, supporting both clinical and commercial-stage biocatalysis programs.
Canada is emerging as the fastest-growing country market at an estimated CAGR of 8.70%, supported by expanding federal investment in biomanufacturing capacity. Evonik's September 2026 disclosure of a CAD 150 million good manufacturing practice drug-product facility investment in the country illustrates the broader wave of biomanufacturing capital entering Canada that is expected to benefit adjacent enzyme and biocatalyst production capabilities over the forecast period. This trajectory positions Canada to gradually narrow the country-level gap with the United States' currently dominant regional market share as biomanufacturing infrastructure matures.
Competitive Landscape
The industry is fragmented, with North America biocatalysts market companies ranging from large diversified life-sciences and specialty chemical conglomerates to focused biocatalysis and contract-manufacturing specialists competing across type, source, application, and country segments. Established players operate across the full biocatalyst value chain, from enzyme discovery and strain engineering through fermentation, formulation, and application-specific technical support for food, agriculture, biofuel, cleaning, and pharmaceutical customers.
Competitive dynamics among North America biocatalysts market players are increasingly shaped by the depth of enzyme-engineering platforms, the scale of fermentation and formulation capacity, and the strength of regulatory and quality infrastructure supporting pharmaceutical biocatalysis applications. Manufacturers are investing in platform consolidation, digital and AI-assisted enzyme-discovery tools, and expanded North American production footprints to secure long-term relationships with food, agriculture, biofuel, and biopharmaceutical customers.
Novonesis Group (Novozymes A/S)
Formed in 2024 through the merger of Novozymes A/S and Chr. Hansen Holding A/S, and headquartered in Bagsværd, Denmark, Novonesis is a leading global biosolutions company supplying industrial and specialty enzymes, microbial cultures, and biocatalysts for food, agriculture, household care, bioenergy, and pharmaceutical applications. The company celebrated a major expansion of its West Allis, Wisconsin production facility in September 2026, strengthening its North American dairy-enzyme manufacturing and innovation capabilities.
Codexis, Inc.
Founded in 2002 and headquartered in Redwood City, California, Codexis is a protein-engineering company that designs and manufactures engineered enzyme biocatalysts for pharmaceutical, therapeutics, and industrial applications through its proprietary CodeEvolver and ECO Synthesis platforms. The company signed an agreement in September 2026 with a pioneering siRNA drug innovator to apply its ECO Synthesis manufacturing platform to the production of stereo-defined siRNA fragments.
DSM-Firmenich AG
Formed in 2023 through the merger of Royal DSM and Firmenich, and dual-headquartered on Kaag Island, Netherlands, and in Satigny, Switzerland, DSM-Firmenich supplies nutrition, health, flavor, and fragrance ingredients, including enzyme solutions for food, feed, and beverage manufacturing. The company completed the sale of its stake in the Feed Enzymes Alliance to Novonesis for USD 1.5 billion in June 2025, refocusing its portfolio on its core nutrition and flavor businesses.
BASF SE
Founded in 1865 and headquartered in Ludwigshafen am Rhein, Germany, BASF is a diversified global chemical producer whose portfolio includes industrial and feed enzymes, including phytase, xylanase, glucanase, and mannanase products, manufactured through its BASF Enzymes unit. The company disclosed in October 2025 that it was evaluating strategic options, including new ownership partners, for its feed enzymes business within its Nutrition & Health segment.
Other key players in the North America biocatalysts market include BRAIN Biotech AG (Biocatalysts Ltd.), Sterling Pharma Solutions Limited, AB Enzymes GmbH, Almac Group Limited, and Amano Enzyme Inc., among others.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Key Highlights of the North America Biocatalysts Market Report
- Comprehensive evaluation of hydrolase, oxidoreductase, and transferase enzyme demand trends across food, industrial, and pharmaceutical biocatalysis applications.
- In-depth analysis of microorganism, plant, and animal enzyme sourcing dynamics shaping production economics across the region.
- Detailed competitive benchmarking of diversified life-sciences conglomerates and focused biocatalysis specialists operating across the United States and Canada.
- Regional opportunity analysis covering the United States' established enzyme-manufacturing dominance alongside Canada's accelerating biomanufacturing investment momentum.
- Strategic insights into enzyme-platform consolidation and biocatalytic drug-manufacturing adoption, examining how these are reshaping competitiveness across the industry.
Why Rely on Expert Market Research?
- Industry-focused analysts tracking evolving enzyme-engineering platforms and biocatalytic drug-manufacturing adoption across the market.
- Research combining producer strategies, fermentation and formulation capacity investment, and application-specific adoption trends shaping competitive outcomes.
- Robust methodology integrating primary interviews with verified secondary intelligence.
- Actionable business recommendations supporting investment, expansion, and market entry decisions.
- Forward-looking insights identifying emerging biocatalysis and AI-assisted enzyme-discovery technology developments.
Call to Action
Unlock the latest insights with our North America biocatalysts market trends 2026 report. Discover country-level growth patterns, type, source, and application trends, and key industry players. Stay ahead of competition with trusted data and expert analysis. Download your free sample report today and drive informed decisions in the market.
More Insights On
Pricing Plans
Upto 15% Off
USD
-
$2499 $2249
-
$3999 $3599
-
$4999 $4249
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Frequently Asked Questions About This Report
In 2025, the market reached an approximate value of 51.06 KMT.
The market is projected to grow at a CAGR of 5.60% between 2026 and 2035.
The market is expected to attain a volume of 88.05 KMT by 2035.
Pursuing enzyme-platform consolidation and strategic divestment of non-core business lines, expanding biocatalytic drug-manufacturing capabilities through AI-assisted discovery platforms, and investing in regionally located fermentation and formulation capacity to serve United States and Canadian customers directly.
The key trends of the market include the increasing collaborations among industry leaders and research institutions, the development of new biocatalytic production technologies, and government grants to promote environmental sustainability through biocatalysts.
The major countries in the market are the United States and Canada.
The various types of biocatalysts considered in the market report are hydrolases, oxidoreductases, and transferases, among others.
The major applications of biocatalysts considered are food and beverages, cleaning agents, biofuel production, agriculture and feed, and biopharmaceuticals, among others.
The various segments based on sources are microorganisms, plants, and animals.
The key players in the market include Novonesis Group (Novozymes A/S), Codexis, Inc., DSM-Firmenich AG, BASF SE, BRAIN Biotech AG (Biocatalysts Ltd.), Sterling Pharma Solutions Limited, AB Enzymes GmbH, Almac Group Limited, and Amano Enzyme Inc., among others.
Manufacturers face high enzyme-discovery and protein-engineering development costs, complex regulatory and quality requirements for pharmaceutical biocatalysis applications, and the technical challenge of scaling fermentation-based enzyme production while maintaining consistent product purity and activity.
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Source |
|
| Breakup by Application |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 2,499
USD 2,249
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,999
USD 3,599
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,999
USD 4,249
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
